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examination of 2 patients revealed PCR positivity with a 3 or 4- 
log increases of normalized BCR-ABL amount and subsequent 
hematologic relapse, which occurred 2 and 4 months later, respec- 
tively. Although our data should be interpreted cautiously, the 
presence of chronic GVHD may reduce the risk of relapse in Ph+ 
ALL. Real-time quantitative RT-PCR appears to be a useful test 
for BCR-ABL transcript monitoring. 
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ALLOGRAFTING WITH FLUDARABINE AND ATG AFTER FAILED 
ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS 
Bayer, R.; Focazio, B.; Johl~, V.; Loscalz~o, ft.; Buchbi~der, A. North 
Shore UlTiversity Hospital, Ma~hasset, NK 
High-dose myeloablative r gimens with autologous stem cell 
transplantation have been pursued as a consolidation strategy in 
first remission AML patients. We report two patients with AML 
who received autologous tem cell transplants in first CR. Both 
patients received similar regimens and failed to engraft heir 
autologous blood stem cells. Both were then given Fludarabine 
and ATG with subsequent engraftment of cells from an HLA 
matched sibling. Patient A.S. is a 32 y.o male diagnosed with 
AML, FAB subtype M2, with normal cytogenetics who received 
induction chemotherapy with Ara-C 100mg/m2 x7 days, 
Daunorubicin 40mg/m2 x3 and VP16 40mg/m2 x3. His intensifi- 
cation/mobil ization i cluded Ara-C 2gin/m2 x8 and VPI6 
10mg/kg x4. The regimen used for autologous stem cell transplant 
was Busulfan p.o. lmg/kg x16 doses and VP16 60mg/kg xl. He 
received 15.6 x 10 E6 CD34 cells/kg bodyweight. On day 52 there 
was no sign of engraftment. He was then given Fludarabine 
30mg/m2 x4 doses and ATG 15mg/kg x6 doses. Peripheral blood 
stem cells, 4.2 x 10 E6 CD34 cells/kg, were given from his HLA 
matched brother. Engraftment was noted on Day 12 post trans- 
plant. He had no signs of GVHD. He is now 100% donor, con- 
firmed by variable number tandem repeats (VNTR). Patient R.S. 
is a 46 y.o male who was diagnosed with AML, FAB subtype M2, 
with normal cytogenetics. His induction chemotherapy consisted 
ofAra-C 100mg/m2 x7 days and Daunorubicin 30rag/m2 x3 days. 
This was followed by an intensification/mobilization regimen of 
Ara-C 2gm/m2 x8 doses and VP16 10mg/kg x4 doses. He received 
Busulfan 1V 0.8mg/kg x16 doses and VP16 60mg/kg xl dose as a 
regimen for his autologous stem cell transplant. He received 11 x 
10 E6 CD34 cells/kg bodyweight. On day 36 there was no 
engraftment. He was then given Fludarabine 30rag/m2 x4 doses 
and ATG 15mg/kg x6 doses. He was given peripheral blood stem 
cells, 2.1 x 10 E6 CD34 cells, from his HLA matched brother. 
Engraftment was noted on Day 7 post transplant. The patient 
developed Grade I GVHD which responded to treatment with 
Prednisone. He is presently 98% donor confirmed by VNTR. We 
conclude that Fludarabine and Antithymocyte globulin is a safe 
and effective regimen for allografting after failed engraftment of
autologous peripheral blood stem cells in patients with AML. 
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THE CD4 PEPTIDE ANALOGUE 802-2 INHIBITS PROLIFERATION 
OF BOTH THI AND TH2 CELLS IN RESPONSE TO ALLOGENEIC 
STIMULATION 
Zbu, Z.; Mooketjee, B.; Ko~zgold, R.; Flome~berg, N. Tbomas Jeffer- 
so~ University School of Medich~e, Philadelphia, PA. 
Engagement of CD4 and the T cell ?eceptor (TCR)-CD3 com- 
plex generates signals which lead, in part, to the activation of 
helper T (Th) cells. Activated Th cells contribute to graft-versus- 
host disease (GVHD) arising from allogeneic MHC class II and 
minor histocompatibility antigenic differences. The 802-2 syn- 
thetic cyclic heptapeptide, designed and confirmed by NMR spec- 
troscopy to mimic the D1-CC' loop of CD4, inhibits Th cell acti- 
vation in human and murine systems. Since Th l  cells appear to be 
more important in the pathogenesis of acute GVHD than their 
Th2 counterparts, the efficacy of 802-2 in modulating allogeneic 
responses of both Th l  and Th2 cells was therefore tested. Prima- 
i T polarization of Th cells was performed by stimulating purified 
CD4+ cells from healthy donors with irradiated EBV transformed 
B cells (EBV-B) obtained from unrelated, HLA ntismatched 
donors in the presence ofTh l  (IL-2 + IL-12) or Th2 (IL-2 + IL- 
4) polarizing cytokines. After similar restimulation on days 3 and 
6, cells were subsequently propagated in the presence irradiated 
autologous mononuclear cells through weekly allogeneic restimn- 
lation and biweekly cytokine supplementation. Th l  and Th2 cells 
from 3-4 week old cultures were harvested and stimulated with 
irradiated EBV-B in the presence of IL-2 with and without 802-2 
peptide. The presence of 802-2 (200gM) reduced the proliferation 
of both Thl  and Th2 cells to near background levels. Delaying 
exposure to 802-2 by more than 72 hours after allogeneic stimula- 
tion substantially reduced or eliminated its ability to inhibit prolif- 
eration. While murine Th cells, activated in vivo, in the presence 
of 802-2 appear to undergo apoptosis, it has not been possible to 
similarly demonstrate apoptosis of human Th cells activated in 
vitro in the presence of 802-2. The lack of inhibitory effects of 
802-2 when added at later time points after allostimulation rules 
out a non-specific inhibition of cellular proliferation or toxicity. 
We hypothesize that 802-2 inhibits multimerization of the 
CD4/MHC class-II/antigen/TCR complex during allostinmla- 
tion. The resultant spatial disruption of the associated signaling 
molecules leads to abrogation of the signals for cell proliferation 
and may render the Th cells anergic, as occurs in other situations 
where lymphocytes receive partial or disordered activation signals. 
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ADDING MYCOPHENOLATE MOFETIL (MMF) AND ATGAM TO 
CYCLOSPORIN DECREASES SEVERE GVHD AND TRANSPLANT-RELAT- 
ED MORTALITY (TRM) AFTER NON-MYELOABLATIVE ALLOGENEIC 
PBSC TRANSPLANTATION (MINI-PBSCT) 
SchwareT; A.P.; Spe~ce~, A.; Kapusc#~ski, M.; ~/btirhead, ,7.Boise Mar- 
row Tra~lsplantatio~, Alfi'ed Hospital, Melbou~n~e, 7C, Amtralia. 
INTRODUCTION:  Mini-PBSCT can provide cure for some 
older or less fit patients with hematological malignancies not eligi- 
ble for standard PBSCT. Mini-PBSCT uses lower doses of condi- 
tioning chemotherapy and/or radiotherapy to improve the safety 
of allogeneic PBSCT and relies on the graft-versus-tumor (GVT) 
effect for cure. METHODS: We treated 31 patients, not eligible 
for standard PBSCT, with mini-PBSCT: median age 51 (29-63) 
yrs; 20 male, 11 female; 25 advanced isease (6 AML)CR1, 5 
NHL, 4 myeloma, 2 MDS, 2 HD, 2 mycosis fungoides, and 1 
each of CML-BC, YValdenstom's macroglobulinemia, myelofibro- 
sis, T-PLL) and 6 early disease (2 AML-CR1, 2 CLL, l CML, 1 
LG-NHL). All patients received fludarabine (25 mg/m 2 x5) and 
melphalan 140 mg/rn 2prior to undergoing HLA-matched (22 sib- 
ling, 1 cousin, 8 unrelated) donor mini-PBSCT. The first 12 
patients received CSA 3 mg/m2/day M alone as GVHD prophy- 
laxis in an attempt o not excessively inhibit a potential GVT 
effect. An unacceptably high incidence of severe acute GVHD and 
TRM occurred with a low relapse rate. Therefore, we modified 
the protocol to include ATGAM 15 mg/kg from day 4 to +5 and 
MMF 15 mg/m 2 from day 0 to +27 for all subsequent patients 
(n=19). RESULTS:  Although more patients in 
CSA/ATGANUMMF cohort than CSA alone cohort underwent 
mini-PBSCT with unrelated onors (42% vs 0%) the incidence of
severe acute and extensive chronic GVHD was less, 100 day TRM 
was less (see Table) and overall TRM was less (26% vs 42%; 
p=0.38) in CSA/ATGAM/MMF cohort. To date, the relapse rate 
was similar in both cohorts although the follow-up of survivors 
was shorter in CSA/ATGAMJMMF cohort - 504 (19-634) days vs 
942 (865-1089) days. CHIMERISM:  T cell and myeloid 
chimerism using VNTR polymorphism analysis was assessed in 
CSA/ATGAM/MMF cohort but not the earlier CSA alone 
cohort. Of 14 evaluable patients 13 showed sustained >90-95% 
donor chinaerism by 1 month post mini-PBSCT. The remaining 
patient achieved <50% donor chimerism which was managed by 
ceasing MMF; >90% donor chimerism rapidly developed accom- 
panied by the onset of severe acute GVHD. No graft rejection 
was noted in either cohort. CONCLUSION: The combination 
of CSA/ATGAM/MMF appears to be effective GVHD prophy- 
laxis for older, less fit patients with advanced isease undergoing 
mini-PBSCT. 
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